PTC Therapeutics Reports Positive Topline Results from Month 24 Interim Analysis of PIVOT-HD Extension Study of Votoplam

- Dose-dependent benefit on cUHDRS in Stage 2 participants compared to matched natural history cohort, with 52% slowing at 10 mg dose - - Continued evidence of favorable safety profile - - Novartis initiated global Phase 3 INVEST-HD study of votoplam - - PTC will host a conference call to...